165 related articles for article (PubMed ID: 16523373)
1. Perspectives in gynecologic oncology -- Third European Conference.
Horiot JC
IDrugs; 2006 Mar; 9(3):154-6. PubMed ID: 16523373
[No Abstract] [Full Text] [Related]
2. Perspectives in central nervous system malignancies.
Stummer W
IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
[No Abstract] [Full Text] [Related]
3. Systemic therapy for metastatic renal cell carcinoma.
Kroog GS; Motzer RJ
Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
[TBL] [Abstract][Full Text] [Related]
4. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
5. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
6. Recent advances in the systemic treatment of metastatic papillary renal cancer.
Chowdhury S; Choueiri TK
Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
[TBL] [Abstract][Full Text] [Related]
7. Molecule of the month. Temsirolimus.
Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
[No Abstract] [Full Text] [Related]
8. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
9. Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.
Jacobs C
Clin J Oncol Nurs; 2009 Apr; 13(2):149-53. PubMed ID: 19349261
[No Abstract] [Full Text] [Related]
10. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Bellmunt J; Calvo E; Castellano D; Climent MA; Esteban E; García del Muro X; González-Larriba JL; Maroto P; Trigo JM
Cancer Chemother Pharmacol; 2009 Mar; 63 Suppl 1():S1-13. PubMed ID: 19259675
[TBL] [Abstract][Full Text] [Related]
11. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
14. New drugs for ovarian cancer.
Kaye SB
Clin Adv Hematol Oncol; 2008 Feb; 6(2):91-3. PubMed ID: 18347558
[No Abstract] [Full Text] [Related]
15. Black and white: rapamycin as a regulator of cardiac mTOR signaling.
Madamanchi N; Patterson C
Cell Cycle; 2009 Jun; 8(11):1646. PubMed ID: 19454842
[No Abstract] [Full Text] [Related]
16. American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer.
Eskander RN; Tewari KS
Int J Gynecol Cancer; 2014 Jan; 24(1):13-8. PubMed ID: 24300468
[TBL] [Abstract][Full Text] [Related]
17. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Raj N; Reidy-Lagunes D
Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
[TBL] [Abstract][Full Text] [Related]
18. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic targets.
Farley J; Birrer MJ
Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
[No Abstract] [Full Text] [Related]
20. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Liu X; Lorusso P; Mita M; Piha-Paul S; Hong DS; Fu S; McQuinn L; Asatiani E; Doyle LA; Chen HX; Hess KR; Kurzrock R; Naing A
Oncologist; 2014 Apr; 19(4):426-8. PubMed ID: 24668327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
